Carmot Therapeutics Raises $150M in Series E Equity Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Page 9 - Column Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Column Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Column Group Today - Breaking & Trending Today
How Citizens Financial Group survived
Citizens’ Financial Group’s CEO weighs in on how the regional bank is braving the banking crisis and beyond.
Source: fortune.com
Circle Pharma's first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting
Press Release Circle Pharma announced today that two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic…
Source: venturebeat.com
RAPT Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.88) Per Share, HC Wainwright Forecasts (NASDAQ:RAPT)
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of RAPT Therapeutics in a research note issued on Tuesday, March 21st. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.88) per share for the quarter. HC Wainwright currently […]
Source: modernreaders.com
Head-To-Head Contrast: Draganfly (NASDAQ:DPRO) versus AERWINS Technologies (NASDAQ:AWIN)
HC Wainwright reiterated their buy rating on shares of RAPT Therapeutics (NASDAQ:RAPT – Get Rating) in a report published on Tuesday, Benzinga reports. They currently have a $43.00 price target on the stock. HC Wainwright also issued estimates for RAPT Therapeutics’ Q1 2024 earnings at ($0.88) EPS, Q2 2024 earnings at ($0.91) EPS, Q3 2024 […]
Source: dailypolitical.com